| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 18 | 2022 | 56 | 6.600 |
Why?
|
| Glioblastoma | 23 | 2024 | 264 | 6.350 |
Why?
|
| Brain Neoplasms | 31 | 2024 | 783 | 6.220 |
Why?
|
| Immunotherapy | 15 | 2024 | 693 | 2.630 |
Why?
|
| Glioma | 14 | 2022 | 294 | 2.450 |
Why?
|
| Tryptophan | 10 | 2022 | 97 | 1.810 |
Why?
|
| Kynurenine | 6 | 2022 | 21 | 1.580 |
Why?
|
| Disease Models, Animal | 15 | 2020 | 2392 | 1.160 |
Why?
|
| Neoplasms | 11 | 2024 | 3062 | 1.090 |
Why?
|
| T-Lymphocytes, Regulatory | 9 | 2016 | 312 | 1.060 |
Why?
|
| Mice | 38 | 2024 | 11846 | 1.020 |
Why?
|
| Animals | 52 | 2024 | 27516 | 0.970 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2020 | 173 | 0.850 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2020 | 203 | 0.790 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 4 | 2021 | 135 | 0.780 |
Why?
|
| Brain | 7 | 2022 | 2303 | 0.770 |
Why?
|
| Facial Nerve | 3 | 2010 | 34 | 0.730 |
Why?
|
| Cell Line, Tumor | 15 | 2024 | 2583 | 0.720 |
Why?
|
| Tryptophan Oxygenase | 2 | 2019 | 9 | 0.680 |
Why?
|
| Motor Neurons | 5 | 2012 | 176 | 0.670 |
Why?
|
| Enzyme Assays | 1 | 2019 | 16 | 0.660 |
Why?
|
| Antigens, CD | 5 | 2021 | 466 | 0.610 |
Why?
|
| Immune Tolerance | 1 | 2020 | 341 | 0.590 |
Why?
|
| Radiation, Ionizing | 1 | 2018 | 123 | 0.580 |
Why?
|
| B7-H1 Antigen | 3 | 2020 | 278 | 0.580 |
Why?
|
| Aging | 3 | 2024 | 726 | 0.580 |
Why?
|
| Salmonella typhimurium | 1 | 2017 | 33 | 0.570 |
Why?
|
| Flagellin | 1 | 2017 | 18 | 0.570 |
Why?
|
| Tumor Microenvironment | 11 | 2024 | 476 | 0.550 |
Why?
|
| Humans | 58 | 2024 | 89864 | 0.540 |
Why?
|
| Facial Nerve Injuries | 4 | 2012 | 11 | 0.540 |
Why?
|
| Killer Cells, Natural | 4 | 2024 | 276 | 0.540 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 3 | 2021 | 32 | 0.530 |
Why?
|
| Mice, Inbred C57BL | 14 | 2024 | 3250 | 0.510 |
Why?
|
| Enzyme Inhibitors | 2 | 2018 | 644 | 0.500 |
Why?
|
| Neoplasms, Experimental | 3 | 2019 | 269 | 0.500 |
Why?
|
| CTLA-4 Antigen | 2 | 2020 | 140 | 0.490 |
Why?
|
| Mice, Knockout | 8 | 2020 | 2015 | 0.480 |
Why?
|
| Signal Transduction | 4 | 2021 | 3403 | 0.420 |
Why?
|
| Th2 Cells | 3 | 2010 | 147 | 0.410 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2021 | 484 | 0.370 |
Why?
|
| Astrocytoma | 1 | 2011 | 82 | 0.370 |
Why?
|
| Th1 Cells | 3 | 2015 | 166 | 0.360 |
Why?
|
| Thymus Gland | 1 | 2011 | 197 | 0.360 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 2328 | 0.360 |
Why?
|
| 5'-Nucleotidase | 2 | 2020 | 13 | 0.350 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2010 | 135 | 0.340 |
Why?
|
| Interleukin-17 | 1 | 2010 | 105 | 0.340 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2010 | 35 | 0.340 |
Why?
|
| Membrane Glycoproteins | 2 | 2011 | 431 | 0.340 |
Why?
|
| Biomarkers, Tumor | 2 | 2015 | 1542 | 0.330 |
Why?
|
| Chemokines | 1 | 2009 | 74 | 0.330 |
Why?
|
| Blood-Brain Barrier | 2 | 2021 | 75 | 0.300 |
Why?
|
| Mice, Transgenic | 5 | 2020 | 1576 | 0.300 |
Why?
|
| Energy Metabolism | 2 | 2021 | 282 | 0.300 |
Why?
|
| Inflammation | 3 | 2024 | 981 | 0.290 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1394 | 0.290 |
Why?
|
| Neoplasm Proteins | 2 | 2021 | 538 | 0.290 |
Why?
|
| Prognosis | 6 | 2020 | 3789 | 0.270 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2011 | 323 | 0.260 |
Why?
|
| Dendritic Cells | 3 | 2021 | 451 | 0.250 |
Why?
|
| Molecular Targeted Therapy | 3 | 2017 | 279 | 0.250 |
Why?
|
| Survival Analysis | 3 | 2018 | 1497 | 0.240 |
Why?
|
| Biomarkers | 3 | 2022 | 1774 | 0.240 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily C | 1 | 2024 | 8 | 0.240 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2024 | 599 | 0.240 |
Why?
|
| Cell Survival | 6 | 2020 | 983 | 0.240 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2021 | 276 | 0.230 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2024 | 16 | 0.230 |
Why?
|
| Adenoviridae | 4 | 2018 | 349 | 0.230 |
Why?
|
| Clinical Trials as Topic | 4 | 2021 | 1134 | 0.220 |
Why?
|
| Vitiligo | 2 | 2016 | 17 | 0.220 |
Why?
|
| Axotomy | 4 | 2012 | 8 | 0.220 |
Why?
|
| STAT3 Transcription Factor | 2 | 2021 | 86 | 0.210 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2012 | 449 | 0.210 |
Why?
|
| Oncolytic Viruses | 1 | 2022 | 24 | 0.210 |
Why?
|
| CLOCK Proteins | 1 | 2022 | 15 | 0.200 |
Why?
|
| Drug Repositioning | 1 | 2021 | 23 | 0.190 |
Why?
|
| Skin | 3 | 2016 | 589 | 0.190 |
Why?
|
| Up-Regulation | 3 | 2020 | 726 | 0.190 |
Why?
|
| Fluoxetine | 1 | 2021 | 41 | 0.190 |
Why?
|
| Aged | 9 | 2023 | 19230 | 0.190 |
Why?
|
| Cellular Reprogramming | 1 | 2021 | 41 | 0.190 |
Why?
|
| Meningeal Neoplasms | 1 | 2021 | 66 | 0.190 |
Why?
|
| Drug Synergism | 2 | 2020 | 307 | 0.190 |
Why?
|
| Receptors, Cell Surface | 2 | 2021 | 288 | 0.180 |
Why?
|
| Gene Knockdown Techniques | 2 | 2012 | 247 | 0.180 |
Why?
|
| Male | 18 | 2024 | 42614 | 0.180 |
Why?
|
| Kynurenic Acid | 1 | 2020 | 7 | 0.180 |
Why?
|
| Adaptive Immunity | 2 | 2018 | 167 | 0.170 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2020 | 55 | 0.170 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2020 | 105 | 0.170 |
Why?
|
| Dementia | 1 | 2022 | 203 | 0.170 |
Why?
|
| Autophagy | 1 | 2021 | 159 | 0.170 |
Why?
|
| DNA Damage | 1 | 2021 | 373 | 0.170 |
Why?
|
| RNA, Small Interfering | 2 | 2012 | 557 | 0.170 |
Why?
|
| Melanoma, Experimental | 1 | 2020 | 111 | 0.170 |
Why?
|
| Cognitive Dysfunction | 1 | 2022 | 155 | 0.170 |
Why?
|
| Insect Proteins | 1 | 2000 | 89 | 0.170 |
Why?
|
| Gene Expression | 3 | 2014 | 1309 | 0.160 |
Why?
|
| Female | 19 | 2024 | 46529 | 0.160 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2020 | 201 | 0.160 |
Why?
|
| Astrocytes | 2 | 2010 | 142 | 0.160 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 196 | 0.160 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 1704 | 0.160 |
Why?
|
| DNA Methylation | 1 | 2023 | 664 | 0.160 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2018 | 39 | 0.160 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2000 | 160 | 0.160 |
Why?
|
| Phosphoproteins | 1 | 2000 | 261 | 0.160 |
Why?
|
| Lectins, C-Type | 1 | 2018 | 86 | 0.150 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2011 | 693 | 0.150 |
Why?
|
| Repressor Proteins | 2 | 2010 | 423 | 0.150 |
Why?
|
| Immunologic Factors | 1 | 2019 | 171 | 0.150 |
Why?
|
| HeLa Cells | 1 | 2019 | 515 | 0.150 |
Why?
|
| Flow Cytometry | 4 | 2013 | 690 | 0.150 |
Why?
|
| Immune Evasion | 1 | 2018 | 35 | 0.150 |
Why?
|
| Neoplasm Transplantation | 3 | 2013 | 397 | 0.150 |
Why?
|
| Melanoma | 1 | 2021 | 471 | 0.140 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2024 | 520 | 0.140 |
Why?
|
| Myeloid Cells | 2 | 2015 | 101 | 0.140 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2024 | 91 | 0.140 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 785 | 0.140 |
Why?
|
| Positron-Emission Tomography | 1 | 2018 | 337 | 0.140 |
Why?
|
| GPI-Linked Proteins | 2 | 2019 | 51 | 0.140 |
Why?
|
| Toll-Like Receptors | 1 | 2017 | 92 | 0.140 |
Why?
|
| Enzyme Activation | 1 | 2018 | 696 | 0.140 |
Why?
|
| Chemokine CCL2 | 1 | 2016 | 47 | 0.140 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2021 | 32 | 0.140 |
Why?
|
| Antigens, Neoplasm | 1 | 2018 | 334 | 0.130 |
Why?
|
| Doxorubicin | 2 | 2014 | 293 | 0.130 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2016 | 26 | 0.130 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2016 | 12 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2022 | 1283 | 0.130 |
Why?
|
| Tuberous Sclerosis | 1 | 2015 | 30 | 0.130 |
Why?
|
| Base Sequence | 3 | 2016 | 2329 | 0.130 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2000 | 663 | 0.130 |
Why?
|
| Drug Delivery Systems | 2 | 2013 | 178 | 0.120 |
Why?
|
| Catalysis | 1 | 2015 | 205 | 0.120 |
Why?
|
| Nuclear Proteins | 1 | 2000 | 727 | 0.120 |
Why?
|
| Disease Management | 1 | 2017 | 327 | 0.120 |
Why?
|
| Ligands | 3 | 2021 | 447 | 0.120 |
Why?
|
| Drosophila Proteins | 1 | 2000 | 510 | 0.120 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2015 | 91 | 0.120 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2015 | 86 | 0.120 |
Why?
|
| Skin Transplantation | 1 | 1996 | 184 | 0.120 |
Why?
|
| Immunity | 1 | 2015 | 141 | 0.120 |
Why?
|
| Family Practice | 2 | 2005 | 83 | 0.120 |
Why?
|
| Metal Nanoparticles | 1 | 2014 | 31 | 0.120 |
Why?
|
| Extracellular Matrix | 1 | 1996 | 245 | 0.120 |
Why?
|
| Gold | 1 | 2014 | 41 | 0.120 |
Why?
|
| Burns | 1 | 1996 | 141 | 0.110 |
Why?
|
| Heme Oxygenase-1 | 1 | 2013 | 20 | 0.110 |
Why?
|
| Microglia | 2 | 2016 | 108 | 0.110 |
Why?
|
| Adult | 10 | 2021 | 26784 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 112 | 0.110 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 159 | 0.110 |
Why?
|
| Cell Lineage | 1 | 2015 | 293 | 0.110 |
Why?
|
| Micelles | 1 | 2013 | 48 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2000 | 1244 | 0.110 |
Why?
|
| Dacarbazine | 1 | 2014 | 101 | 0.110 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 1066 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2016 | 395 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 854 | 0.110 |
Why?
|
| Fibrin | 1 | 2013 | 86 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 1096 | 0.110 |
Why?
|
| Interleukin-12 | 1 | 2014 | 111 | 0.110 |
Why?
|
| Drug Carriers | 1 | 2013 | 82 | 0.110 |
Why?
|
| Middle Aged | 9 | 2021 | 26103 | 0.110 |
Why?
|
| Financial Management | 1 | 1993 | 21 | 0.110 |
Why?
|
| Neural Stem Cells | 1 | 2013 | 58 | 0.110 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 173 | 0.110 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2012 | 4 | 0.100 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2012 | 5 | 0.100 |
Why?
|
| Survival Rate | 2 | 2020 | 1898 | 0.100 |
Why?
|
| Rats | 2 | 2017 | 4048 | 0.100 |
Why?
|
| Oligopeptides | 1 | 2013 | 188 | 0.100 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 2000 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 76 | 0.100 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2012 | 27 | 0.100 |
Why?
|
| Antibodies, Neoplasm | 1 | 2012 | 84 | 0.100 |
Why?
|
| Genetic Therapy | 2 | 2014 | 372 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 105 | 0.100 |
Why?
|
| Mutation | 1 | 2023 | 4164 | 0.100 |
Why?
|
| Nanoparticles | 1 | 2013 | 164 | 0.100 |
Why?
|
| Transcription Factors | 1 | 2000 | 1665 | 0.100 |
Why?
|
| Thymectomy | 1 | 2011 | 31 | 0.100 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 1221 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 1130 | 0.090 |
Why?
|
| RNA, Messenger | 3 | 2017 | 2025 | 0.090 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 2368 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 6779 | 0.090 |
Why?
|
| Oncolytic Virotherapy | 1 | 2010 | 42 | 0.090 |
Why?
|
| Fibronectins | 1 | 2010 | 101 | 0.090 |
Why?
|
| Chemokine CXCL11 | 1 | 2009 | 2 | 0.090 |
Why?
|
| Chemokine CCL11 | 1 | 2009 | 11 | 0.090 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2010 | 59 | 0.090 |
Why?
|
| Immunity, Cellular | 1 | 2010 | 178 | 0.080 |
Why?
|
| Interleukin-10 | 1 | 2010 | 155 | 0.080 |
Why?
|
| DNA Primers | 1 | 2010 | 543 | 0.080 |
Why?
|
| Nerve Regeneration | 1 | 2009 | 36 | 0.080 |
Why?
|
| Immunity, Innate | 2 | 2011 | 433 | 0.080 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2009 | 48 | 0.080 |
Why?
|
| Central Nervous System | 1 | 2010 | 153 | 0.080 |
Why?
|
| Lymphocyte Activation | 3 | 2021 | 754 | 0.080 |
Why?
|
| Superoxide Dismutase | 1 | 2009 | 177 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 919 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 840 | 0.080 |
Why?
|
| Facial Nerve Diseases | 1 | 2007 | 3 | 0.080 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2009 | 188 | 0.070 |
Why?
|
| Apoptosis | 2 | 2013 | 1717 | 0.070 |
Why?
|
| Cell Movement | 3 | 2016 | 786 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 511 | 0.070 |
Why?
|
| Disease Progression | 1 | 2011 | 1469 | 0.070 |
Why?
|
| Macrophages | 2 | 2021 | 581 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2021 | 816 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 1452 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 1048 | 0.060 |
Why?
|
| Musculoskeletal Diseases | 1 | 2005 | 34 | 0.060 |
Why?
|
| Analysis of Variance | 2 | 2018 | 899 | 0.060 |
Why?
|
| Transduction, Genetic | 2 | 2018 | 160 | 0.060 |
Why?
|
| Genetic Vectors | 2 | 2018 | 446 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2015 | 8264 | 0.060 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2024 | 71 | 0.060 |
Why?
|
| Pain Management | 1 | 2005 | 143 | 0.060 |
Why?
|
| Receptors, CCR4 | 2 | 2016 | 3 | 0.060 |
Why?
|
| Glutathione | 1 | 2024 | 108 | 0.060 |
Why?
|
| Lactic Acid | 1 | 2024 | 93 | 0.060 |
Why?
|
| HEK293 Cells | 2 | 2018 | 646 | 0.060 |
Why?
|
| Cell Count | 2 | 2015 | 199 | 0.050 |
Why?
|
| Lymph Nodes | 2 | 2018 | 550 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2021 | 9185 | 0.050 |
Why?
|
| Symbiosis | 1 | 2024 | 127 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 3021 | 0.050 |
Why?
|
| Pain | 1 | 2005 | 399 | 0.050 |
Why?
|
| ARNTL Transcription Factors | 1 | 2022 | 11 | 0.050 |
Why?
|
| Sphingomyelins | 1 | 2021 | 16 | 0.050 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2021 | 21 | 0.050 |
Why?
|
| CD11c Antigen | 1 | 2021 | 13 | 0.050 |
Why?
|
| Permeability | 1 | 2021 | 138 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2022 | 182 | 0.050 |
Why?
|
| Immunologic Surveillance | 1 | 2021 | 14 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2022 | 235 | 0.050 |
Why?
|
| Neuroimaging | 1 | 2022 | 116 | 0.050 |
Why?
|
| Tumor Escape | 1 | 2021 | 51 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 388 | 0.040 |
Why?
|
| Transplantation, Isogeneic | 1 | 2020 | 40 | 0.040 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2020 | 37 | 0.040 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2020 | 78 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 310 | 0.040 |
Why?
|
| Coronary Vessels | 1 | 2022 | 192 | 0.040 |
Why?
|
| England | 2 | 2005 | 38 | 0.040 |
Why?
|
| Age Factors | 2 | 2020 | 1880 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2020 | 86 | 0.040 |
Why?
|
| Synapses | 1 | 2022 | 280 | 0.040 |
Why?
|
| Solubility | 1 | 2020 | 184 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2012 | 793 | 0.040 |
Why?
|
| Cellular Senescence | 1 | 2020 | 100 | 0.040 |
Why?
|
| Animals, Genetically Modified | 1 | 2000 | 183 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 374 | 0.040 |
Why?
|
| Mesoderm | 1 | 2000 | 124 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2000 | 283 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2000 | 205 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2000 | 178 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2000 | 154 | 0.040 |
Why?
|
| Cancer Survivors | 1 | 2020 | 95 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2021 | 498 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 885 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2000 | 177 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 1083 | 0.040 |
Why?
|
| Morphogenesis | 1 | 2000 | 207 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 563 | 0.040 |
Why?
|
| Homeostasis | 1 | 2020 | 418 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2021 | 351 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 521 | 0.040 |
Why?
|
| Spleen | 1 | 2018 | 433 | 0.040 |
Why?
|
| Cognition | 1 | 2022 | 579 | 0.040 |
Why?
|
| Societies, Scientific | 1 | 2017 | 42 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2017 | 176 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2021 | 384 | 0.030 |
Why?
|
| State Medicine | 2 | 1995 | 12 | 0.030 |
Why?
|
| Transfection | 1 | 2018 | 909 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2016 | 77 | 0.030 |
Why?
|
| Clone Cells | 1 | 2016 | 214 | 0.030 |
Why?
|
| Basement Membrane | 1 | 1996 | 55 | 0.030 |
Why?
|
| Immunodominant Epitopes | 1 | 2015 | 20 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 1996 | 144 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 1996 | 143 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2000 | 3024 | 0.030 |
Why?
|
| Hospitals, Public | 1 | 1995 | 15 | 0.030 |
Why?
|
| Hospital Information Systems | 1 | 1995 | 8 | 0.030 |
Why?
|
| Ovalbumin | 1 | 2015 | 109 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2022 | 2886 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2000 | 1158 | 0.030 |
Why?
|
| Drosophila melanogaster | 1 | 2000 | 614 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 2016 | 645 | 0.030 |
Why?
|
| Phenotype | 1 | 2021 | 2450 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2015 | 214 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 1996 | 347 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 1168 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 3468 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2010 | 1669 | 0.030 |
Why?
|
| Carbocyanines | 1 | 2013 | 18 | 0.030 |
Why?
|
| Protoporphyrins | 1 | 2013 | 19 | 0.030 |
Why?
|
| Metalloporphyrins | 1 | 2013 | 26 | 0.030 |
Why?
|
| Nanomedicine | 1 | 2013 | 14 | 0.030 |
Why?
|
| Wound Healing | 1 | 1996 | 361 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 1996 | 785 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 3670 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2013 | 136 | 0.030 |
Why?
|
| Budgets | 1 | 1993 | 10 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2014 | 142 | 0.030 |
Why?
|
| Pilot Projects | 1 | 1996 | 871 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2015 | 463 | 0.030 |
Why?
|
| Practice Management, Medical | 1 | 1993 | 23 | 0.030 |
Why?
|
| Vaccination | 1 | 2015 | 278 | 0.030 |
Why?
|
| Fibroblasts | 1 | 1996 | 759 | 0.030 |
Why?
|
| Lysosomes | 1 | 2013 | 113 | 0.030 |
Why?
|
| Hybridomas | 1 | 2012 | 75 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2014 | 215 | 0.030 |
Why?
|
| Antibody Affinity | 1 | 2012 | 38 | 0.030 |
Why?
|
| Cricetulus | 1 | 2012 | 127 | 0.030 |
Why?
|
| Cell Death | 1 | 2013 | 261 | 0.030 |
Why?
|
| CHO Cells | 1 | 2012 | 188 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2013 | 503 | 0.030 |
Why?
|
| Glycosylation | 1 | 2012 | 128 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 1993 | 121 | 0.020 |
Why?
|
| Graft Survival | 1 | 1996 | 907 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 434 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1054 | 0.020 |
Why?
|
| Cricetinae | 1 | 2012 | 558 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 2505 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 368 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 283 | 0.020 |
Why?
|
| Leupeptins | 1 | 2010 | 22 | 0.020 |
Why?
|
| Interleukin-10 Receptor alpha Subunit | 1 | 2010 | 1 | 0.020 |
Why?
|
| G2 Phase | 1 | 2010 | 33 | 0.020 |
Why?
|
| Integrin beta1 | 1 | 2010 | 33 | 0.020 |
Why?
|
| Interleukin-10 Receptor beta Subunit | 1 | 2010 | 3 | 0.020 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2010 | 53 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2010 | 33 | 0.020 |
Why?
|
| Sigmodontinae | 1 | 2010 | 4 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2010 | 74 | 0.020 |
Why?
|
| Adolescent | 2 | 2010 | 9327 | 0.020 |
Why?
|
| Receptors, CCR8 | 1 | 2010 | 1 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 303 | 0.020 |
Why?
|
| Receptors, CCR5 | 1 | 2010 | 18 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2010 | 169 | 0.020 |
Why?
|
| Immune System | 1 | 2011 | 97 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 1993 | 345 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2010 | 97 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 1091 | 0.020 |
Why?
|
| Virus Replication | 1 | 2011 | 326 | 0.020 |
Why?
|
| Contrast Media | 1 | 2014 | 1084 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2010 | 262 | 0.020 |
Why?
|
| Cell Division | 1 | 2010 | 692 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2010 | 449 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 1130 | 0.020 |
Why?
|
| RNA | 1 | 2012 | 583 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 1993 | 654 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2007 | 217 | 0.020 |
Why?
|
| Pain, Intractable | 1 | 2005 | 10 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2005 | 26 | 0.020 |
Why?
|
| Upper Extremity | 1 | 2005 | 53 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2010 | 2887 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 5357 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2005 | 281 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 460 | 0.010 |
Why?
|
| Sex Factors | 1 | 2005 | 1074 | 0.010 |
Why?
|
| Neurons | 1 | 2010 | 1589 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 1858 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2005 | 2324 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 6389 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2005 | 2649 | 0.010 |
Why?
|
| Hospital Bed Capacity, 300 to 499 | 1 | 1995 | 4 | 0.010 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1995 | 5 | 0.010 |
Why?
|
| Systems Integration | 1 | 1995 | 36 | 0.010 |
Why?
|
| Confidentiality | 1 | 1995 | 78 | 0.010 |
Why?
|
| United Kingdom | 1 | 1995 | 165 | 0.010 |
Why?
|
| Health Policy | 1 | 1995 | 188 | 0.010 |
Why?
|